Joseph Walker, MD
Surgery · Donalsonville, GANPI 1396866943
Payments from drug & device makers
Across 213 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$1K
- Novo Nordisk$690
- GSK$279
- AstraZeneca$224
- Sanofi$146
- Kowa Pharmaceuticals America, Inc.$130
- plus $729 from 21 others
What the payments were for
- Food & beverage$3,340100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 92 | $1,144 |
| Novo Nordisk | 40 | $690 |
| GSK | 15 | $279 |
| AstraZeneca | 13 | $224 |
| Sanofi | 8 | $146 |
| Kowa Pharmaceuticals America, Inc. | 9 | $130 |
| Elucent Medical | 1 | $105 |
| Regeneron Healthcare Solutions, Inc. | 5 | $94 |
| Eisai Inc. | 4 | $80 |
| Lilly USA, LLC | 5 | $73 |
| Novartis | 2 | $43 |
| Amgen | 2 | $39 |
| Boehringer Ingelheim | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Averitas Pharma Inc. | 1 | $22 |
| Pfizer | 1 | $21 |
| Almatica Pharma LLC | 1 | $20 |
| Merz North America, Inc. | 1 | $20 |
| Exact Sciences | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| UCB, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| AbbVie | 1 | $11 |
| Merck | 1 | $11 |
How this compares
$3,340 in reported general payments places this provider in the 60th percentile of 855 surgery providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $74,070 |
| EliquisApixaban | 114 | $63,746 |
| MounjaroTirzepatide | 51 | $55,735 |
| FarxigaDapagliflozin Propanediol | 78 | $55,534 |
| JardianceEmpagliflozin | 80 | $49,833 |
| Bydureon BciseExenatide Microspheres | 27 | $22,494 |
| LinzessLinaclotide | 41 | $21,643 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $15,775 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $15,254 |
| EntrestoSacubitril/Valsartan | 18 | $13,499 |
| XareltoRivaroxaban | 22 | $12,347 |
| LivaloPitavastatin Calcium | 18 | $11,884 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 19 | $3,660 |
| MyrbetriqMirabegron | 14 | $3,521 |
| Megestrol Acetate | 55 | $2,612 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $690 | $74,07074 claims |
| PfizerEliquis | $21 | $63,746114 claims |
| Lilly USA, LLCMounjaro, Humulin 70-30 | $73 | $57,49073 claims |
| AstraZenecaFarxiga | $224 | $55,53478 claims |
| Boehringer IngelheimJardiance | $37 | $49,83380 claims |
| AbbVieLinzess, Synthroid | $11 | $22,56162 claims |
| GSKTrelegy Ellipta | $279 | $15,77525 claims |
| NovartisEntresto | $43 | $13,49918 claims |
| Johnson & JohnsonXarelto | $14 | $12,34722 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $130 | $11,88418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 855 surgery providers in Georgia.
Other surgery in Donalsonville
- Idelberto BadellAtlanta$3.9M
- Chad CopperGainesville$999K
- Zachary KlaassenAugusta$763K
- Kendra GrubbAtlanta$761K
- Stephen OdomAustell$599K
- Fritz Jean-PierreMarietta$464K
- Nelson RoyallGainesville$415K
- Denise LoAtlanta$309K
- Christian LarsenAtlanta$308K
- Harry LightfootSmyrna$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.